Increasing Adherence with Topical Agents for Atopic Dermatitis
Abstract Atopic dermatitis (AD) is an intensely pruritic dermatosis that develops most commonly during early infancy and childhood and may follow a chronic, relapsing course into adulthood. As a chronic disease, AD requires treatment over an extended period of time, and is therefore difficult to treat. The main difficulty stems from poor adherence to treatment by patients for reasons such as frustration with medication efficacy, inconvenience, and fear of side effects. Methods that improve adherence include creating therapeutic plans with patient preferences in mind, early follow-up visit, increasing patient education through workshops, and discussing with patients and their caretakers their fears about treatment methods. AD can be exceedingly detrimental to a patient’s quality of life. Simple measures to improve adherence may improve patients’ treatment outcomes and quality of life..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
American journal of clinical dermatology - 18(2017), 3 vom: 24. Feb., Seite 323-332 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patel, Nupur U. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Atopic Dermatitis |
|---|
| doi: |
10.1007/s40257-017-0261-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR032965583 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR032965583 | ||
| 003 | DE-627 | ||
| 005 | 20230519150812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40257-017-0261-5 |2 doi | |
| 035 | |a (DE-627)SPR032965583 | ||
| 035 | |a (SPR)s40257-017-0261-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Patel, Nupur U. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increasing Adherence with Topical Agents for Atopic Dermatitis |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Atopic dermatitis (AD) is an intensely pruritic dermatosis that develops most commonly during early infancy and childhood and may follow a chronic, relapsing course into adulthood. As a chronic disease, AD requires treatment over an extended period of time, and is therefore difficult to treat. The main difficulty stems from poor adherence to treatment by patients for reasons such as frustration with medication efficacy, inconvenience, and fear of side effects. Methods that improve adherence include creating therapeutic plans with patient preferences in mind, early follow-up visit, increasing patient education through workshops, and discussing with patients and their caretakers their fears about treatment methods. AD can be exceedingly detrimental to a patient’s quality of life. Simple measures to improve adherence may improve patients’ treatment outcomes and quality of life. | ||
| 650 | 4 | |a Atopic Dermatitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Topical Corticosteroid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pimecrolimus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Atopic Dermatitis Patient |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Topical Medication |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a D’Ambra, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Steven R. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of clinical dermatology |d Berlin [u.a.] : Springer, 2000 |g 18(2017), 3 vom: 24. Feb., Seite 323-332 |w (DE-627)SPR032954131 |w (DE-600)2043675-0 |x 1179-1888 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2017 |g number:3 |g day:24 |g month:02 |g pages:323-332 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40257-017-0261-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2017 |e 3 |b 24 |c 02 |h 323-332 | ||